210 related articles for article (PubMed ID: 23774432)
1. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.
Jones SA; Murakami E; Delaney W; Furman P; Hu J
Antimicrob Agents Chemother; 2013 Sep; 57(9):4181-9. PubMed ID: 23774432
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.
Clark DN; Hu J
Antiviral Res; 2015 Nov; 123():132-7. PubMed ID: 26408354
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
4. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5'-triphosphate of fialuridine.
Staschke KA; Colacino JM
J Virol; 1994 Dec; 68(12):8265-9. PubMed ID: 7525986
[TBL] [Abstract][Full Text] [Related]
5. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of reverse transcriptase activity of hepatitis B virus polymerase by β-l-D4A-TP.
Wang XY; Gao LL; Hu ZH; Wang HL; Deng F; Jin JS
Acta Virol; 2008; 52(1):47-52. PubMed ID: 18459835
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.
Seifer M; Hamatake RK; Colonno RJ; Standring DN
Antimicrob Agents Chemother; 1998 Dec; 42(12):3200-8. PubMed ID: 9835515
[TBL] [Abstract][Full Text] [Related]
11. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
12. Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.
Xu X; Thai H; Kitrinos KM; Xia G; Gaggar A; Paulson M; Ganova-Raeva L; Khudyakov Y; Lara J
BMC Bioinformatics; 2016 Aug; 17 Suppl 8(Suppl 8):280. PubMed ID: 27587008
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.
Menéndez-Arias L; Álvarez M; Pacheco B
Curr Opin Virol; 2014 Oct; 8():1-9. PubMed ID: 24814823
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.
Kwon SY; Park YK; Ahn SH; Cho ES; Choe WH; Lee CH; Kim BK; Ko SY; Choi HS; Park ES; Shin GC; Kim KH
J Virol; 2010 May; 84(9):4494-503. PubMed ID: 20164224
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.
Rawal RK; Konreddy AK; Chu CK
Curr Med Chem; 2015; 22(34):3922-32. PubMed ID: 26336997
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.
Rhee SY; Margeridon-Thermet S; Nguyen MH; Liu TF; Kagan RM; Beggel B; Verheyen J; Kaiser R; Shafer RW
Antiviral Res; 2010 Dec; 88(3):269-75. PubMed ID: 20875460
[TBL] [Abstract][Full Text] [Related]
17. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
[TBL] [Abstract][Full Text] [Related]
18. Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.
Nakajima S; Watashi K; Fukano K; Tsukuda S; Wakae K; Aizaki H; Muramatsu M; Wakita T; Toyoda T
J Gastroenterol; 2020 Apr; 55(4):441-452. PubMed ID: 31768802
[TBL] [Abstract][Full Text] [Related]
19. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies.
Chong Y; Chu CK
Bioorg Med Chem Lett; 2002 Dec; 12(23):3459-62. PubMed ID: 12419383
[TBL] [Abstract][Full Text] [Related]
20. Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.
van Hemert FJ; Berkhout B; Zaaijer HL
PLoS One; 2014; 9(9):e106324. PubMed ID: 25180507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
